NasdaqCM:HTBX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$159.2m

Last Updated

2021/08/04 23:08 UTC

Data Sources

Company Financials +

Executive Summary

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Heat Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HTBX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: HTBX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-5.0%

HTBX

2.7%

US Biotechs

0.02%

US Market


1 Year Return

-58.9%

HTBX

28.3%

US Biotechs

33.2%

US Market

Return vs Industry: HTBX underperformed the US Biotechs industry which returned 24.9% over the past year.

Return vs Market: HTBX underperformed the US Market which returned 34.7% over the past year.


Shareholder returns

HTBXIndustryMarket
7 Day-5.0%2.7%0.02%
30 Day-7.5%3.5%-0.1%
90 Day-4.1%12.7%4.1%
1 Year-58.9%-58.9%30.1%28.3%35.3%33.2%
3 Year-56.9%-56.9%10.8%5.8%61.4%51.3%
5 Year-94.3%-94.3%49.1%36.9%122.2%97.7%

Long-Term Price Volatility Vs. Market

How volatile is Heat Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Heat Biologics undervalued compared to its fair value and its price relative to the market?

1.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HTBX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: HTBX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HTBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HTBX is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Heat Biologics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

30.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HTBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HTBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HTBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HTBX's revenue (85.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: HTBX's revenue (85.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HTBX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Heat Biologics performed over the past 5 years?

-12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HTBX is currently unprofitable.

Growing Profit Margin: HTBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HTBX is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare HTBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HTBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).


Return on Equity

High ROE: HTBX has a negative Return on Equity (-20.25%), as it is currently unprofitable.


Financial Health

How is Heat Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: HTBX's short term assets ($133.9M) exceed its short term liabilities ($3.0M).

Long Term Liabilities: HTBX's short term assets ($133.9M) exceed its long term liabilities ($5.0M).


Debt to Equity History and Analysis

Debt Level: HTBX is debt free.

Reducing Debt: HTBX has no debt compared to 5 years ago when its debt to equity ratio was 150.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HTBX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: HTBX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.4% each year


Dividend

What is Heat Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HTBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HTBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HTBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Jeff Wolf (58 yo)

13.17yrs

Tenure

US$6,419,937

Compensation

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D., is the Chief Executive Officer and President of Heat Biologics, Inc. since August 2008 and served as its Treasurer and Secretary. Mr. Wolf Co-Founded Pelica...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD6.42M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HTBX's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: HTBX's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HTBX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.9%.


Top Shareholders

Company Information

Heat Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heat Biologics, Inc.
  • Ticker: HTBX
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$159.242m
  • Shares outstanding: 25.40m
  • Website: https://www.heatbio.com

Number of Employees


Location

  • Heat Biologics, Inc.
  • 627 Davis Drive
  • Suite 400
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings


Biography

Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. Its gp96 platfor...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/04 23:08
End of Day Share Price2021/08/04 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.